Cargando…

P14. Cell-based gene delivery leverages conventional immunotherapy for cancer

Detalles Bibliográficos
Autores principales:	Günther, C, Huss, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072448/ http://dx.doi.org/10.1186/2051-1426-2-S2-P5

Ejemplares similares

Chitosan thermogels for local T lymphocyte delivery for cancer immunotherapy
por: Monette, Anne, et al.
Publicado: (2015)

P15-26. Leveraging motivators to participation in HIV vaccine research in the age of Obama
por: Alexander, SB, et al.
Publicado: (2009)

P02.39. Leveraging grant awards to enhance the research infrastructure at a CAM institution
por: Pohlman, K, et al.
Publicado: (2012)

P-052: LEVERAGING PLASMA-DERIVED EXOSOMES FOR BIOMARKER DISCOVERY IN SICKLE CELL DISEASE: PREPARATION FOR A LARGE PROSPECTIVE STUDY
por: Y., LAMARRE, et al.
Publicado: (2022)

P59. Depleting the suppressors for the benefit of immunotherapy against cervical cancer
por: Draghiciu, O, et al.
Publicado: (2014)

Optimizing the delivery of chemotherapy in the setting of immunotherapy in a preclinical glioblastoma model
por: Mathios, Dimitrios, et al.
Publicado: (2015)

Cancer-specific T cell receptor isolation for cancer immunotherapy
por: Baker, Debbie Emma, et al.
Publicado: (2015)

Immunotherapy targeting esophageal cancer stem cells
por: Yue, Dongli, et al.
Publicado: (2013)

P14-08. Intramuscular DNA delivery by electroporation leads to greatly enhanced systemic and mucosal immune responses and control of SIVmac251 challenge
por: Pavlakis, GN, et al.
Publicado: (2009)

P58. Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
por: Jallad, S, et al.
Publicado: (2014)

P64. T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma
por: Dargel, C, et al.
Publicado: (2014)

Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer
por: Puri, Sachin, et al.
Publicado: (2014)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

A novel biomarker assay for cancer immunotherapy development based on myeloid derived supressor cells (MDSCs)
por: Hepburne-Scott, Henry
Publicado: (2013)

Prevalence of mesquite (prosopis species) allergy and efficacy of conventional allergen specific Immunotherapy (ASIT) to mesquite in Egyptian patients with perennial allergic rhinitis (PAR)
por: Farag-Mahmod, Farag I, et al.
Publicado: (2010)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

Exploitation of gamma delta T cells in cancer immunotherapy as combined antigen-presenters and cancer cell killers
por: Holmen Olofsson, Gitte, et al.
Publicado: (2014)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients
por: Pandha, Hardev, et al.
Publicado: (2015)

Tumor-induced suppressive CD8+ T cells: implications for cancer immunotherapy
por: Pfannenstiel, Lukas W, et al.
Publicado: (2013)

P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
por: Pellegatta, S, et al.
Publicado: (2014)

Gene expression profile of CD8 T cells from the responder and non-responder mice following immunotherapy treatment for prostate cancer
por: Dubey, Seema, et al.
Publicado: (2013)

P16. Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: a potential mechanism for the NK cell-based immunotherapy efficacy
por: Sconocchia, G, et al.
Publicado: (2014)

P04.80. Navigating the divide: women's engagement with conventional and complementary medicine in pregnancy
por: Steel, A, et al.
Publicado: (2012)

Immunological changes after one year of specific immunotherapy with Pru p 3
por: Gomez, Francisca, et al.
Publicado: (2015)

P05.14. Educating medical students in clinical perception: an evaluation study
por: Edelhäuser, F, et al.
Publicado: (2012)

P02.14. Efficacy of ah shi point acupuncture on acne vulgaris
por: Son, B, et al.
Publicado: (2012)

Recent advances in adoptive cancer immunotherapy in china
por: Zhou, Juhua
Publicado: (2015)

P03.14. Cancer complementary and alternative medicine research among NCI’s cancer centers program and the integrative medicine programs: an inventory
por: Mikhail, I, et al.
Publicado: (2012)

P11. Developing an immunotherapy strategy for the effective treatment of patients with Non Small Cell Lung Cancer (NSCLC): strategies to evaluate immunity in patients on clinical trials
por: Neuberger, M, et al.
Publicado: (2014)

Specific increase in T cell potency via structure-based design of a T cell receptor for adoptive immunotherapy
por: Malecek, Karolina, et al.
Publicado: (2014)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

P-14 Multiple acyl-coa dehydrogenase deficiency: a possibly treatable condition
por: Todeschini, A., et al.
Publicado: (2011)

P08-14 The association of childhood commuting modes and physical activity in adult age
por: Kaseva, Kaisa, et al.
Publicado: (2022)

Identification of novel immune checkpoints as targets for cancer immunotherapy
por: Levy, Ofer, et al.
Publicado: (2014)

Engineering the immune response to "self" for effective cancer immunotherapy
por: Zhong, Shi, et al.
Publicado: (2014)

Identification of novel immune checkpoints as targets for cancer immunotherapy
por: Rotman, Galit, et al.
Publicado: (2013)

T lymphocyte engineering with cytokine nanogels for enhanced cancer immunotherapy
por: Tang, Li, et al.
Publicado: (2015)

P19-43. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform
por: Weber, C, et al.
Publicado: (2009)

Clinical scale labeling of T cell immunotherapy for MRI cell tracking
por: Helfer, Brooke M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7thfrh2gc3tpgj1uctjbgnia1g